Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic Carcinoma

Blasko, John C.; Wallner, Kent E.; Grimm, Peter; Ragde, Haakon

doi:10.1097/00005392-199509000-00052

Cited by 52 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Implantation of seeds in the periprostatic tissues particularly near the prostatic apex and base is a common practice. 5 This practice allows radiation to be delivered to extraprostatic sites but, in some instances, may be limited because a small portion of seeds may migrate through the venous circulation and become lodged in pulmonary capillaries. 40,41 The data presented here indicate that few sites of EPE are found near the bladder base or prostatic apex.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, prostate brachytherapy with temporary or permanent placement of radionuclides has reemerged as an alternative method of treatment for patients with clinically localized prostate carcinoma. This resurgence has stemmed from technical advances in the use of transrectal ultrasound (TRUS) for needle guidance with perineal templates 4,5 and computed tomography (CT) and TRUS-based dosimetry with sophisticated treatment planning software.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The radial distance of extraprostatic extension of prostate carcinoma

Davis

Pisansky

Wilson

et al. 1999

Cancer

145

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

The radial distance of extraprostatic extension of prostate carcinoma

Davis

Pisansky

Wilson

et al. 1999

Cancer

145

View full text Add to dashboard Cite

“…However, the use of PSA testing to monitor therapeutic efficacy is not ideal, since PSA is not specific for prostate cancer. Additionally, it can take 1-2 years or more for PSA levels to reach nadir values following radiation therapy (both external beam and brachytherapy) (81,82). Further, the interpretation of PSA data is more complicated for patients undergoing therapies, such as hormone deprivation therapy, that have a direct effect on the production of PSA.…”

Section: Current Clinical Applicationsmentioning

confidence: 99%

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Kurhanewicz

Swanson

Nelson

et al. 2002

Magnetic Resonance Imaging

333

266

View full text Add to dashboard Cite

Magnetic resonance spectroscopic imaging (MRSI) provides a noninvasive method of detecting small molecular markers (historically the metabolites choline and citrate) within the cytosol and extracellular spaces of the prostate, and is performed in conjunction with high-resolution anatomic imaging. Recent studies in pre-prostatectomy patients have indicated that the metabolic information provided by MRSI combined with the anatomical information provided by MRI can significantly improve the assessment of cancer location and extent within the prostate, extracapsular spread, and cancer aggressiveness. Additionally, pre-and post-therapy studies have demonstrated the potential of MRI/MRSI to provide a direct measure of the presence and spatial extent of prostate cancer after therapy, a measure of the time course of response, and information concerning the mechanism of therapeutic response. In addition to detecting metabolic biomarkers of disease behavior and therapeutic response, MRI/MRSI guidance can improve tissue selection for ex vivo analysis. High-resolution magic angle spinning ( 1 H HR-MAS) spectroscopy provides a full chemical analysis of MRI/MRSI-targeted tissues prior to pathologic and immunohistochemical analyses of the same tissue. Preliminary 1 H HR-MAS spectroscopy studies have already identified unique spectral patterns for healthy glandular and stromal tissues and prostate cancer, determined the composition of the composite in vivo choline peak, and identified the polyamine spermine as a new metabolic marker of prostate cancer. The addition of imaging sequences that provide other functional information within the same exam (dynamic contrast uptake imaging and diffusion-weighted imaging) have also demonstrated the potential to further increase the accuracy of prostate cancer detection and characterization.

show abstract

“…The reasons for the increase are many, including patient convenience (one treatment versus many for external‐beam radiotherapy), reduced side effects as compared with radical prostatectomy, and greater cost effectiveness. ( 1 – 4 ) With a shortage of available seeds and an increase in the number of procedures being performed nationally, several manufacturers, including IsoAid (IsoAid LLC, Port Richey, FL), have developed new

{}^{103}{Pd}

sources to meet the increasing demand.…”

Section: Introductionmentioning

confidence: 99%

Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE brachytherapy source

Sowards

2007

J Applied Clin Med Phys

View full text Add to dashboard Cite

For roughly 25 years, normalI125 and Pd103 sources have been used in the treatment of various malignant diseases such as prostate cancer. Various new sources have been marketed and produced to meet the demand for new sources to use in treatment. Recently, IsoAID LLC created the ADVANTAGE Pd103 source. Various dosimetric parameters must be determined to facilitate treatment planning using this source. Theoretical determination of dosimetric characteristics, dose rate constant, radial dose function, and anisotropy function for this new source followed the American Association of Physicists in Medicine (AAPM) Task Group 43U1 recommendations. Theoretical calculations were performed in liquid water using the PTRAN Monte Carlo code version 7.44. The radial dose function of the new source was calculated in liquid water at distances up to 10.0 cm, and the anisotropy function, at distances ranging from 0.5 cm to 7.0 cm. The anisotropy factors and anisotropy constant were derived from the anisotropy function. The results in water indicate that the dose rate constant is 0.709±0.014 cGy•normalh−1•normalU−1 and that the anisotropy constant is 0.880±0.040. The dosimetric characteristics of this new source compare favorably with those of other commercially available Pd103 sources.PACS: 87.53.Jw

show abstract

Prostate Specific Antigen Based Disease Control Following Ultrasound Guided sup 125 Iodine Implantation for Stage T1/T2 Prostatic Carcinoma

Abstract: There is a high rate of clinical and chemical freedom from progression following 125I implantation for select patients with early stage prostatic carcinoma.

Cited by 52 publications

References 0 publications

The radial distance of extraprostatic extension of prostate carcinoma

The radial distance of extraprostatic extension of prostate carcinoma

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Monte Carlo dosimetric characterization of the IsoAid ADVANTAGE brachytherapy source

Contact Info

Product

Resources

About